The Future of Cervical Cancer Screening: HPV Extended Genotyping, Risk Stratification, and Beyond

The Future of Cervical Cancer Screening: HPV Extended Genotyping, Risk Stratification, and Beyond

The Future of Cervical Cancer Screening: HPV Extended Genotyping, Risk Stratification, and Beyond
Dr. Huh discusses new emerging CCS technology, HPV screening updates, and advances in extended genotyping technology.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    While cervical cancer is less common in the United States than in prior years, the American Cancer Society estimates that there are 12,820 new cases and 4,210 deaths in 2017. Despite the decreasing morbidity and mortality associated with cervical cancer, there remains marked uncertainty among healthcare providers regarding the optimal screening strategy.

    Join Warner Huh, MD as he discusses practice adoption barriers for new emerging CCS/extended genotyping technology, updates in the guidelines for the screening, diagnosis, and management of HPV disease; and advances in extended genotyping technology.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Warner K. Huh, MD
    Margaret Cameron Spain Endowed Chair in Obstetrics/Gynecology
    University of Alabama in Birmingham
    Birmingham, AL

    Dr. Huh receives consulting fees from Incell Dx and TheVax.


    • Sean T. Barrett has nothing to disclose.
    • Ken Brown has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Teach awareness of developing CCS diagnostic tools and extended genotyping methods
    • Discuss practice adoption barriers for new emerging CCS/extended genotyping technology, based on scientific and medical validity of the concept
    • Discuss new advances in context to the harmonized guidelines from ACS, ASCP, ASCCP, and USPSTF for the screening, diagnosis, and management of HPV disease
    • Demonstrate and practice use of extended genotyping methods to stratify risk, lessen overtreatment, and reduce colposcopy
  • Target Audience

    This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from BD Life Sciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Omnia Education newsletters.
Comprehensive women’s health CME.

Better education for a better you.

* Required

Join Omnia Education's community of women's health professionals.
Registration is free and easy.

Register Now